Who is sponsoring NCT05638334?

NCT05638334 is sponsored by Institut de Recherches Internationales Servier.

What drugs are being tested in NCT05638334?

Interventions in NCT05638334: 89Zr-S095012 tracer and S095012 will be administered via an IV infusion.

What condition does NCT05638334 study?

NCT05638334 studies Advanced Solid Tumor.

Is NCT05638334 still recruiting?

NCT05638334 is currently terminated. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT05638334

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours

Terminated Phase 1 Last updated 17 February 2026

What this trial tests

Phase 1 trial testing 89Zr-S095012 tracer and S095012 will be administered via an IV infusion in Advanced Solid Tumor in 3 participants. Terminated before completion.

Timeline

21 November 2022

Primary endpoint
14 June 2024

14 June 2024

Quick facts

Lead sponsor	Institut de Recherches Internationales Servier
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	21 November 2022
Primary completion	14 June 2024
Estimated completion	14 June 2024
Sites	1 location across Netherlands

Drugs / interventions tested

89Zr-S095012 tracer and S095012 will be administered via an IV infusion — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Institut de Recherches Internationales Servier — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the whole-body biodistribution and tumour uptake of 89Zr-S095012 in participants with solid tumours treated with S095012 (PD-L1x4-1BB bispecific antibody)

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer.
Arasanz H, Chocarro L, Fernández-Rubio L, Blanco E, et al · · 2023 · cited 6× · PMID 37373003 · DOI 10.3390/ijms24129855
Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer.
Wen J, Cui W, Yin X, Chen Y, et al · · 2025 · cited 5× · PMID 40192238 · DOI 10.20892/j.issn.2095-3941.2024.0470
Nuclear Imaging of Bispecific Antibodies on the Rise.
Roohani B, Mendez AS, Dangarwala M, Katz S, et al · · 2024 · cited 4× · PMID 39266295 · DOI 10.2967/jnumed.123.267215
ImmunoPET provides a novel way to visualize the CD103<sup>+</sup> tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.
Fan X, Nijman HW, de Bruyn M, Elsinga PH. · · 2024 · cited 1× · PMID 38182929 · DOI 10.1186/s13550-023-01062-6

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other Institut de Recherches Internationales Servier trials

Trials by the same sponsor.

NCT07227857 — A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopath · Phase 1, PHASE2 · recruiting
NCT06501625 — Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta · Phase 1, PHASE2 · recruiting
NCT06465953 — Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod · Phase 3 · recruiting
NCT06225999 — Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not · Phase 2 · active not recruiting
NCT05674474 — A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hep · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05638334 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut de Recherches Internationales Servier
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05638334.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing